Antimicrobial Dosing in Acute Renal Replacement

被引:30
作者
Fissell, William H. [1 ]
机构
[1] Vanderbilt Univ, Dept Hypertens & Nephrol, Nashville, TN 37232 USA
基金
美国国家卫生研究院;
关键词
Acute kidney injury; Continuous renal replacement therapy; Hemodialysis; Sustained low-efficiency dialysis; Antimicrobial agents; CRITICALLY-ILL PATIENTS; CONTINUOUS VENOVENOUS HEMOFILTRATION; ACUTE KIDNEY INJURY; GLOMERULAR-FILTRATION-RATE; MIDDLE-MOLECULE CLEARANCE; INTENSIVE-CARE PATIENTS; CONTINUOUS-INFUSION; IN-VITRO; PIPERACILLIN-TAZOBACTAM; BETA-LACTAMS;
D O I
10.1053/j.ackd.2012.10.004
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Acute kidney injury (AKI) is a common problem in hospitalized patients and is associated with significant morbidity and mortality. Two large trials showed no benefit from increased doses of renal replacement therapy (RRT) despite previous clinical data suggesting that increased clearance from RRT has beneficial effects. Since infection is the leading cause of death in AKI, my group and others hypothesized that increased RRT antibiotic clearance might create a competing morbidity. The data from my group, as well as those of other groups, show that many patients are underdosed when routine "1 size fits all" antibiotic dosing is used in patients with AKI receiving continuous RRT (CRRT). Here, concepts of drug distribution and clearance in AKI are briefly discussed and then 1 antibiotic (piperacillin) is discussed in depth to illustrate the challenges in applying the medical literature to clinical practice. The fact that published data on drug dosing in AKI and dialysis reflect the evolution of practice patterns and often do not apply to present prescribing habits is also discussed. A more general approach to drug dosing facilitates situation-specific prescribing by the nephrologist and critical care specialist. (C) 2013 by the National Kidney Foundation, Inc. All rights reserved.
引用
收藏
页码:85 / 93
页数:9
相关论文
共 77 条
[21]   CARBOPLATIN DOSAGE - PROSPECTIVE EVALUATION OF A SIMPLE FORMULA BASED ON RENAL-FUNCTION [J].
CALVERT, AH ;
NEWELL, DR ;
GUMBRELL, LA ;
OREILLY, S ;
BURNELL, M ;
BOXALL, FE ;
SIDDIK, ZH ;
JUDSON, IR ;
GORE, ME ;
WILTSHAW, E .
JOURNAL OF CLINICAL ONCOLOGY, 1989, 7 (11) :1748-1756
[22]   Removal of piperacillin in critically ill patients undergoing continuous venovenous hemofiltration [J].
Capellier, G ;
Cornette, C ;
Boillot, A ;
Guinchard, C ;
Jacques, T ;
Blasco, G ;
Barale, F .
CRITICAL CARE MEDICINE, 1998, 26 (01) :88-91
[23]   Intestinal crosstalk: A new paradigm for understanding the gut as the "motor" of critical illness [J].
Clark, Jessica A. ;
Coopersmith, Craig M. .
SHOCK, 2007, 28 (04) :384-393
[24]   High-volume hemofiltration as salvage therapy in severe hyperdynamic septic shock [J].
Cornejo, R ;
Downey, P ;
Castro, R ;
Romero, C ;
Regueira, T ;
Vega, J ;
Castillo, L ;
Andresen, M ;
Dougnac, A ;
Bugedo, G ;
Hernandez, G .
INTENSIVE CARE MEDICINE, 2006, 32 (05) :713-722
[25]   Clinical review: RIFLE and AKIN - time for reappraisal [J].
Cruz, Dinna N. ;
Ricci, Zaccaria ;
Ronco, Claudio .
CRITICAL CARE, 2009, 13 (03) :211
[26]   Gentamicin Pharmacokinetics and Pharmacodynamics during Short-Daily Hemodialysis [J].
Decker, Brian S. ;
Mohamed, Ahmed N. ;
Chambers, Mary ;
Kraus, Michael A. ;
Moe, Sharon M. ;
Sowinski, Kevin M. .
AMERICAN JOURNAL OF NEPHROLOGY, 2012, 36 (02) :144-150
[27]   Estimating renal function in the ICU: even more challenging [J].
Demirjian, Sevag ;
Poggio, Emilio D. .
NATURE REVIEWS NEPHROLOGY, 2011, 7 (10) :549-550
[28]  
DENHARTIGH J, 1983, CANCER RES, V43, P5017
[29]   Established and Emerging Markers of Kidney Function [J].
Ferguson, Michael A. ;
Waikar, Sushrut S. .
CLINICAL CHEMISTRY, 2012, 58 (04) :680-689
[30]   Antibiotics in critically ill patients: a systematic review of the pharmacokinetics of β-lactams [J].
Goncalves-Pereira, Joao ;
Povoa, Pedro .
CRITICAL CARE, 2011, 15 (05)